natgillin/translations-raw huggingface dataset:
In patients with non-valvular atrial fibrillation receiving rivaroxaban for the prevention of stroke and systemic embolism, the 5/95 percentiles for PT (Neoplastin) 1 - 4 hours after tablet intake (i.e. at the time of maximum effect) in patients treated with 20 mg once daily ranged from 14 to 40 s and in patients with moderate renal impairment treated with 15 mg once daily from 10 to 50 s.
U bolesnika koji boluju od nevalvularne fibrilacije atrija i koji rivaroksaban dobivaju za prevenciju moždanog udara i sistemske embolije, trajanje PV-a (Neoplastin) 1-4 sati nakon uzimanja tablete (tj. u vrijeme maksimalnog učinka) kod bolesnika koji dobivaju 20 mg lijeka jedanput na dan u 5% slučajeva je manje od 14 s, a u 5% slučajeva dulje od 40 s, a kod bolesnika s umjereno oštećenom funkcijom bubrega koji dobivaju 15 mg lijeka na dan u 5% slučajeva je manje od 10 s, a u 5% slučajeva dulje od 50 s.
In patients with normal renal function (creatinine clearance > 80 ml/min), high doses of non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen > 1600 mg/day) and aspirin at higher dose (> 1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse events.
U bolesnika s normalnom funkcijom bubrega (klirens kreatinina ≥ 80 ml/min) visoke doze nesteroidnih protuupalnih lijekova (NSAIL, npr. ibuprofen > 1600 mg na dan) i više doze acetilsalicilatne kiseline (≥ 1,3 g na dan) mogu smanjiti eliminaciju pemetrekseda i, posljedično povećati pojavu nuspojava izazvanih pemetreksedom.
In patients with normal renal function (creatinine clearance > 80 ml/min), high doses of non-steroidal anti-inflammatory medicinal product (NSAIDs, such as ibuprofen > 1600 mg/day) and aspirin at higher dose (> 1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse events.
U bolesnika s normalnom funkcijom bubrega (klirens kreatinina ≥ 80 ml/min) visoke doze nesteroidnih protuupalnih lijekova (NSAIL, poput ibuprofena > 1600 mg na dan) i više doze aspirina (≥ 1,3 g na dan) mogu smanjiti eliminaciju pemetrekseda i, posljedično povećati pojavu štetnih događaja izazvanih pemetreksedom.
In patients with normal renal function (creatinine clearance ≥ 80 ml/min), high doses of non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen > 1,600 mg/day) and aspirin at higher dose (≥ 1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse events.
U bolesnika s normalnom funkcijom bubrega (klirens kreatinina ≥ 80 ml/min) visoke doze nesteroidnih protuupalnih lijekova (NSAIL, npr. ibuprofen > 1600 mg na dan) i više doze acetilsalicilatne kiseline (≥ 1,3 g na dan) mogu smanjiti eliminaciju pemetrekseda i, posljedično povećati pojavu nuspojava izazvanih pemetreksedom.
In patients with normal renal function (creatinine clearance ≥ 80 ml/min), high doses of non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen > 1600 mg/day) and aspirin at higher doses (≥ 1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse events.
U bolesnika s normalnom funkcijom bubrega (klirens kreatinina ≥ 80 ml/min) visoke doze nesteroidnih protuupalnih lijekova (NSAIL, npr. ibuprofen > 1600 mg na dan) i više doze acetilsalicilatne kiseline (≥ 1,3 g na dan) mogu smanjiti eliminaciju pemetrekseda i, posljedično povećati pojavu nuspojava izazvanih pemetreksedom.
In patients with normal renal function (creatinine clearance ≥ 80 ml/min), high doses of non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen > 1600 mg/day) and aspirin at higher doses (≥ 1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse events.
U bolesnika s normalnom funkcijom bubrega (klirens kreatinina ≥ 80 ml/min), visoke doze nesteroidnih protuupalnih lijekova (NSAIL, npr. ibuprofen > 1600 mg na dan) i više doze acetilsalicilatne kiseline (≥ 1,3 g na dan) mogu smanjiti eliminaciju pemetrekseda i, posljedično, povećati pojavu nuspojava izazvanih pemetreksedom.
In patients with normal renal function after hip or knee replacement surgery, receiving dabigatran etexilate and verapamil concomitantly, the dose of Pradaxa should be reduced to 150 mg taken once daily as 2 capsules of 75 mg.
U bolesnika s normalnom bubrežnom funkcijom nakon kirurškog zahvata ugradnje endoproteze kuka ili koljena, koji istodobno primaju dabigatraneteksilat i verapamil, doza Pradaxe se snižava na 150 mg jedanput dnevno u obliku 2 kapsule od 75 mg.
In patients with normal renal function after the hip or knee replacement surgery, receiving dabigatran etexilate and verapamil concomitantly, the dose of Pradaxa should be reduced to 150 mg taken once daily as 2 capsules of 75 mg .
U bolesnika s normalnom bubrežnom funkcijom nakon kirurškog zahvata ugradnje endoproteze kuka ili koljena, koji istodobno primaju dabigatraneteksilat i verapamil, doza Pradaxe se snižava na 150 mg jedanput dnevno u obliku 2 kapsule od 75 mg.
In patients with normal renal function, defined as CLcr > 60 ml/min, zoledronic acid 4 mg/100 ml solution for infusion must not be further diluted.
U bolesnika s normalnom funkcijom bubrega, definiranom klirensom kreatinina većim od 60 ml/min, zoledronatna kiselina 4 mg/100 ml otopina za infuziju ne smije se dodatno razrjeđivati.
In patients with ocular disorders, ophthalmological evaluation should be considered if vision disorder persists or worsens in severity.
U bolesnika s poremećajima oka, potrebno je razmotriti oftalmološki pregled ako poremećaj vida ustraje ili se pogoršava u stupnju težine.
In patients with paediatric psoriasis, anti-adalimumab antibodies were identified in 5/38 subjects (13%) treated with 0.8mg/kg adalimumab monotherapy.
U pedijatrijskih bolesnika s psorijazom, protutijela na adalimumab nađena su u 5/38 ispitanika (13%) liječenih monoterapijom adalimumabom u dozi od 0,8 mg/kg.
In patients with Paget’s disease symptoms due to low blood calcium, such as muscle spasms, or numbness, or a tingling sensation especially in the area around the mouth have been reported.
U bolesnika s Pagetovom bolešću zabilježeni su simptomi uzrokovani niskom razinom kalcija u krvi, kao što su grčevi mišića, utrnulost ili trnci, osobito u području oko usta.
In patients with Paget’s disease, it is strongly advised that adequate supplemental calcium corresponding to at least 500 mg elemental calcium twice daily is ensured for at least 10 days following Aclasta administration (see section 4.4).
U bolesnika s Pagetovom bolešću, snažno se preporučuje osigurati uzimanje odgovarajućeg nadomjestka kalcija, koji odgovara količini od najmanje 500 mg elementarnog kalcija, dvaput dnevno, tijekom najmanje 10 dana nakon primjene Aclaste (vidjeti dio 4.4).
In patients with Paget’s disease, it is strongly advised that adequate supplemental calcium corresponding to at least 500 mg elemental calcium twice daily is ensured for at least 10 days following zoledronic acid administration (see section 4.4).
U bolesnika s Pagetovom bolešću, snažno se preporučuje osigurati uzimanje odgovarajućeg nadomjestka kalcija, koji odgovara količini od najmanje 500 mg elementarnog kalcija, dvaput dnevno, tijekom najmanje 10 dana nakon primjene zoledronatne kiseline (vidjeti dio 4.4).
In patients with Paget’s disease, it is strongly advised that adequate supplemental calcium corresponding to at least 500 mg elemental calcium twice daily is ensured for at least 10 days following Zoledronic Acid Hospira administration (see section 4.4).
U bolesnika s Pagetovom bolešću, snažno se preporučuje osigurati uzimanje odgovarajućeg nadomjestka kalcija, koji odgovara količini od najmanje 500 mg elementarnog kalcija, dvaput dnevno, tijekom najmanje 10 dana nakon primjene Zoledronatne kiseline Hospira (vidjeti dio 4.4).
In patients with Paget’s disease, it is strongly advised that adequate supplemental calcium corresponding to at least 500 mg elemental calcium twice daily is ensured for at least 10 days following Zoledronic acid Teva Pharma administration (see section 4.4).
U bolesnika s Pagetovom bolešću, snažno se preporučuje osigurati uzimanje odgovarajućeg nadomjestka kalcija, koji odgovara količini od najmanje 500 mg elementarnog kalcija, dvaput dnevno, tijekom najmanje 10 dana nakon primjene Zoledronatne kiseline Teva Pharma (vidjeti dio 4.4).
In patients with Paget’s disease, symptoms due to low blood calcium, such as muscle spasms, or numbness, or a tingling sensation especially in the area around the mouth have been reported.
Kod bolesnika s Pagetovom bolešću, zabilježeni su simptomi zbog niske razine kalcija u krvi, kao što su grčevi mišića, ili utrnutost, ili osjećaj trnaca osobito u području oko usta.
In patients with Paget’s disease, symptoms due to low blood calcium, such as muscle spasms, or numbness, or a tingling sensation especially in the area around the mouth have been reported.
Kod bolesnika s Pagetovom bolešću: prijavljeni su simptomi uzrokovani niskom razinom kalcija u krvi, kao što su grčevi mišića ili utmutost ili trnci, osobito u području oko usta.
In patients with Paget’s disease, symptoms due to low blood calcium, such as muscle spasms, or numbness, or a tingling sensation especially in the area around the mouth have been reported.
U bolesnika s Pagetovom bolešću zabilježeni su simptomi uzrokovani niskom razinom kalcija u krvi, kao što su grčevi mišića, utrnulost ili trnci, osobito u području oko usta.
In patients with Paget’s disease: symptoms due to low blood calcium, such as muscle spasms, or numbness, or a tingling sensation especially in the area around the mouth have been reported.
U bolesnika s Pagetovom bolešću zabilježeni su simptomi uzrokovani niskom razinom kalcija u krvi, kao što su grčevi mišića, utrnulost ili trnci, osobito u području oko usta.
In patients with PAH, this mechanism is overactive and, by blocking the receptors, macitentan helps widen the arteries in the lungs and thereby bring down the blood pressure.
U bolesnika s PAH-om, ovaj je mehanizam prekomjerno aktivan, a blokirajući receptore macitentan pomaže širenju arterija u plućima šire, te stoga snižava krvni tlak.
In patients with Parkinson's disease, the cells that produce dopamine begin to die and the amount of dopamine in the brain decreases.
U bolesnika s Parkinsonovom bolesti, stanice mozga koje proizvode dopamin počinju odumirati te se smanjuje količina dopamina u mozgu.
In patients with Parkinson’s disease Olanzapine Glenmark Europe may worsen the symptoms
U bolesnika koji boluju od Parkinsonove bolesti, Olanzapin Glenmark Europe može pogoršati simptome.
In patients with Parkinson’s disease Olanzapine Glenmark may worsen the symptoms.
U bolesnika koji boluju od Parkinsonove bolesti, Olanzapin Glenmark može pogoršati simptome.
In patients with Parkinson’s disease Olazax Disperzi may worsen the symptoms
U bolesnika koji boluju od Parkinsonove bolesti, Olazax Disperzi može pogoršati simptome.
In patients with Parkinson’s disease Olazax may worsen the symptoms
U bolesnika koji boluju od Parkinsonove bolesti, Olazax može pogoršati simptome.
In patients with Parkinson’s disease, certain cells in the brain that produce dopamine die, and as dopamine is involved in controlling movement, the patient's movement worsens over time.
U bolesnika s Parkinsonovom bolesti, određene stanice u mozgu koje proizvode dopamin umiru, a budući da je dopamin uključen u kontrolu pokreta, tijekom vremena pogoršava se kretanje bolesnika.
In patients with Parkinson’s disease, multiple-dose pharmacokinetics was comparable to single-dose pharmacokinetics, i.e. there was a minimal accumulation of levodopa from the modified-release levodopa/carbidopa medicinal product.
U bolesnika s Parkinsonovom bolešću, farmakokinetike višestrukih doza usporedive su s farmakokinetikom pojedinačnih doza, tj. postojalo je minimalno nakupljanje levodope iz lijeka s prilagođenim oslobađanjem levodope/karbidope.
In patients with Parkinson’s disease, the cells in the brain that produce dopamine, a neurotransmitter important for controlling movement, begin to die and the amount of dopamine in the brain decreases.
U bolesnika s Parkinsonovom bolešću, stanice mozga koje proizvode dopamin, neurotransmiter koji je važan za kontroliranje pokreta, počinju odumirati te se smanjuje količina dopamina u mozgu.
In patients with Parkinson’s disease, the cells in the brain that produce the neurotransmitter dopamine begin to die and the amount of dopamine in the brain decreases.
U bolesnika oboljelih od Parkinsonove bolesti, stanice u mozgu koje stvaraju neurotransmiter dopamin počinju umirati te se smanjuje količina dopamina u mozgu.
In patients with Parkinson’s disease, the cells in the brain that produce the neurotransmitter dopamine begin to die and the amount of dopamine in the brain decreases.
U bolesnika s Parkinsonovom bolesti stanice mozga koje proizvode neurotransmiter dopamin počinju odumirati i količina dopamina u mozgu se smanjuje.
In patients with Parkinson’s disease, the cells that produce dopamine begin to die and the amount of dopamine in the brain decreases.
Parkinsonovom bolešću stanice koje proizvode dopamin počinju odumirati i stoga se količina dopamina u mozgu smanjuje.
In patients with Parkinson’s disease, the cells that produce dopamine begin to die and the amount of dopamine in the brain decreases.
U bolesnika s Parkinsonovom bolešću stanice koje proizvode dopamin počinju odumirati i stoga se količina dopamina u mozgu smanjuje.
In patients with Parkinson’s disease, the cells that produce dopamine die and the amount of dopamine in the brain decreases.
U bolesnika s Parkinsonovom bolesti, stanice koje proizvode dopamin umiru, a količina dopamina u mozgu se smanjuje.
In patients with patent nasolacrimal ducts, topical ocular administration of OPATANOL was suggested to reduce the nasal signs and symptoms that frequently accompany seasonal allergic conjunctivitis.
Pretpostavlja se da topikalna okularna primjena OPATANOLA u bolesnika s funkcionirajućim nazolakrimalnim kanalićima ublažava nazalne znakove i simptome koji često prate sezonski alergijski konjunktivitis.
In patients with persistent very good partial response, consider other methods to evaluate the depth of response.
U bolesnika s trajnim vrlo dobrim djelomičnim odgovorom, razmotrite druge metode procjene potpunosti odgovora.
In patients with PFI  6 months (65% in Yondelis+PLD and 63% in PLD arm), median PFS was 9.7 months in the Yondelis+PLD arm compared with 7.2 months in the PLD monotherapy arm (HR=0.66, CI: 0.52-0.85).
Kod bolesnika s PFI  6 mjeseci (65 % u skupini uz Yondelis + PLD i 63 % u skupini s PLD- om), medijan PFS-a iznosio je 9,7 mjeseci u skupini koja je primala Yondelis + PLD u usporedbi sa 7,2 mjeseci u skupini koja je primala samo PLD (HR = 0,66, CI: 0,52 – 0,85).
In patients with Ph+ ALL treated with the 140 mg once daily regimen, the median duration of MaHR was 5 months the median PFS was 4 months, and the median overall survival was 7 months.
U bolesnika s Ph+ ALL liječenih dozom od 140 mg jedanput dnevno, medijan trajanja MaHR iznosio je 5 mjeseci, medijan PFS 4 mjeseca, a medijan ukupnog preživljenja 7 mjeseci.
In patients with phenotypic data (n = 66)
U pacijenata s fenotipskim podacima (n = 66)
in patients with Philadelphia chromosome-positive chronic myelogenous leukaemia
leukemijom s pozitivnim Philadelphia kromosomom (Ph+ KML) koji su prethodno
In patients with PNH and aHUS the complement proteins are over-activated and cause damage to the patients’ own blood cells.
Kod bolesnika oboljelih od PNH-a i aHUS-a komplementski proteini prekomjerno su aktivni te uzrokuju oštećenje krvnih stanica bolesnika.
In patients with polyarticular JIA who were 2 to <4 years old or aged 4 and above weighing <15 kg dosed with adalimumab 24 mg/m2 , the mean trough steady-state serum adalimumab concentrations was 6.0 ± 6.1 µg/ml (101% CV) for adalimumab without concomitant methotrexate and 7.9 ± 5.6 µg/ml (71.2% CV) with concomitant methotrexate.
U bolesnika s poliartikularnim JIA u dobi od 2 do manje od 4 godine ili u dobi od 4 godine i starijih i tjelesne težine manje od 15 kg, nakon primjene 24 mg/m2 adalimumaba srednja vrijednost najniže koncentracije adalimumaba u serumu u stanju dinamičke ravnoteže bila je 6,0 ± 6,1 µg/ml (101% CV) za adalimumab bez istodobne primjene metotreksata i 7,9 ± 5,6 µg/ml (71,2% CV) uz istodobnu primjenu metotreksata.
In patients with polyarticular JIA who were 2 to <4 years old or aged 4 and above weighing <15 kg dosed with adalimumab 24 mg/m2, the mean trough steady-state serum adalimumab concentrations was 6.0 ± 6.1 µg/ml (101% CV) for adalimumab without concomitant methotrexate and 7.9 ± 5.6 µg/ml (71.2% CV) with concomitant methotrexate.
U bolesnika s poliartikularnim JIA u dobi od 2 do manje od 4 godine ili u dobi od 4 godine i starijih i tjelesne težine manje od 15 kg, nakon primjene 24 mg/m2 adalimumaba srednja vrijednost najniže koncentracije adalimumaba u serumu u stanju dinamičke ravnoteže bila je 6,0 ± 6,1 µg/ml (101% CV) za adalimumab bez istodobne primjene metotreksata i 7,9 ± 5,6 µg/ml (71,2% CV) uz istodobnu primjenu metotreksata.
In patients with polyarticular juvenile idiopathic arthritis who were 4 to 17 years, anti- adalimumab antibodies were identified in 15.8% (27/171) of patients treated with adalimumab.
U bolesnika s poliartikularnim juvenilnim idiopatskim artritisom u dobi od 4 do 17 godina, protutijela na adalimumab identificirana su u 15,8% (27/171) bolesnika liječenih adalimumabom.
In patients with pre-existing anaemia, leucopenia, and/or thrombocytopenia as well as in patients with impaired bone marrowfunction or those at risk of bone marrowsuppression, the risk of haematological disorders is increased.
U bolesnika s postojećom anemijom, leukopenijom i/ili trombocitopenijom, kao i u bolesnika s oštećenom funkcijom koštane srži ili s rizikom od supresije koštane srži, povećan je rizik od pojave hematoloških poremećaja.
In patients with pre-existing hypokalaemia or those that develop hypokalaemia whilst being treated with ZYTIGA, consider maintaining the patient’s potassium level at ≥ 4.0 mM.
U bolesnika s postojećom hipokalemijom ili u onih kod kojih se razvije hipokalemija tijekom liječenja lijekom ZYTIGA, razmotrite održavanje razine kalija u bolesnika na ≥ 4,0 mM.
In patients with pre-existing or recent onset of demyelinating disorders, the benefits and risks of anti-TNF treatment should be carefully considered before initiation of Inflectra therapy.
U bolesnika s već postojećim ili novonastalim demijelinizacijskim bolestima treba pažljivo procijeniti rizike i koristi anti-TNF terapije prije početka liječenja lijekom Inflectra.
In patients with pre-existing or recent onset of demyelinating disorders, the benefits and risks of anti-TNF treatment should be carefully considered before initiation of Remsima therapy.
U bolesnika s već postojećim ili novonastalim demijelinizacijskim bolestima treba pažljivo procijeniti rizike i koristi anti-TNF terapije prije početka liječenja lijekom Remsima.
In patients with pre-existing or recent onset of demyelinating disorders, the benefits and risks of anti-TNF treatment should be carefully considered before initiation of Simponi therapy.
U bolesnika s već postojećim ili novonastalim demijelinizacijskim bolestima prije početka liječenja lijekom Simponi treba pažljivo procijeniti koristi i rizike anti-TNF terapije.
In patients with pre-existing renal disease leading to hyponatraemia, or in patients concomitantly treated with medicinal products which may themselves lead to hyponatraemia (e.g. diuretics, desmopressin, carbamazepine), serum sodium levels should be examined before and during treatment with eslicarbazepine acetate.
U bolesnika s već postojećom bubrežnom bolešću koja dovodi do hiponatrijemije, ili u bolesnika istodobno liječenih lijekovima koji mogu sami dovesti do hiponatrijemije (npr. diuretici, dezmopresin, karbamazepin), serumska razina natrija treba biti ispitana prije i tijekom liječenja eslikarbazepinacetatom.
In patients with previous immune-mediated thrombocytopaenia from other parenteral GP IIb/IIIa inhibitors, there are no data with the use of INTEGRILIN.
Nema podataka o primjeni INTEGRILINA u bolesnika koji su razvili imunološki posredovanu trombocitopeniju nakon primjene drugih parenteralnih inhibitora GP IIb/IIIa.
In patients with previous immune-mediated thrombocytopenia from other parenteral GP IIb/IIIa inhibitors, there are no data with the use of eptifibatide.
Nema podataka o primjeni eptifibatida u bolesnika koji su razvili imunološki posredovanu trombocitopeniju nakon primjene drugih parenteralnih inhibitora GP IIb/IIIa.
In patients with previously untreated CLL receiving ofatumumab and chlorambucil, the geometric mean Cmax values after the first infusion (300 mg), the 1,000 mg infusion on day 8, and the 1,000 mg infusion at the fourth monthly cycle were 52 g/ml, 241 g/ml, and 285 g/ml, respectively; the geometric mean AUC(0-) value at the fourth cycle was 65,100 g.h/ml.
U bolesnika s prethodno neliječenim KLL-om koji su primali ofatumumab i klorambucil, geometrijska srednja vrijednost Cmax nakon prve infuzije (300 mg) iznosila je 52 μg/ml, nakon infuzije doze od 1000 mg 8. dana 241 μg/ml, a nakon doze od 1000 mg u četvrtom mjesečnom ciklusu 285 μg/ml; geometrijska srednja vrijednost AUC(0-) u četvrtom ciklusu iznosila je 65 100 μg.h/ml.
In patients with previously untreated CLL, the median decreases in B cell counts after the first cycle and prior to the sixth monthly cycle were 94% and >99% respectively for ofatumumab in combination with chlorambucil and 73% and 97% respectively for chlorambucil alone.
U bolesnika s prethodno neliječenim KLL-om, medijan smanjenja broja B-stanica nakon prvog ciklusa odnosno prije šestog mjesečnog ciklusa iznosio je 94% odnosno > 99% za ofatumumab u kombinaciji s klorambucilom te 73% odnosno 97% za klorambucil u monoterapiji.
In patients with prior chemotherapy a benefit was indicated in those with a KPS  80.
Među bolesnicima koji su prethodno primali kemoterapiju korist se vidjela u onih koji su imali KPS ≥ 80.
In patients with prolonged elevations of serum transaminases, it is appropriate to evaluate for other possible causes, such as infection, and referral to a specialist may be required.
U bolesnika s produljenim povišenjima razina serumskih transaminaza, treba procijeniti i druge moguće uzroke, kao što je infekcija, te će možda trebati uputiti bolesnika specijalistu.
In patients with pulmonary arterial hypertension, plasma concentrations of N-desmethyl metabolite are approximately 72 % those of sildenafil after 20 mg three times a day dosing (translating into a 36 % contribution to sildenafil’s pharmacological effects).
U bolesnika s plućnom arterijskom hipertenzijom plazmatske koncentracije N-dezmetil metabolita iznose približno 72% koncentracije sildenafila nakon primjene doze od 20 mg tri puta na dan (što čini doprinos od 36% farmakološkim učincima sildenafila).
In patients with pulmonary arterial hypertension, plasma concentrations of N-desmethyl metabolite are approximately 72 % those of sildenafil after 20 mg three times a day oral dosing (translating into a 36 % contribution to sildenafil’s pharmacological effects).
U bolesnika s plućnom arterijskom hipertenzijom plazmatske koncentracije N-dezmetil metabolita iznose približno 72% koncentracije sildenafila nakon primjene peroralne doze od 20 mg tri puta na dan (što čini doprinos od 36% farmakološkim učincima sildenafila).
In patients with pulmonary arterial hypertension, the average steady state concentrations were 20-50 % higher over the investigated oral dose range of 20–80 mg three times a day compared to healthy volunteers.
U bolesnika s plućnom arterijskom hipertenzijom, prosječne koncentracije u stanju dinamičke ravnoteže su u ispitivanom rasponu peroralnih doza od 20-80 mg tri puta na dan bile 20-50% više nego u zdravih dobrovoljaca.
In patients with refractory CLL, the median decrease in B cell counts was 22% after the first infusion and 92% at the eighth weekly infusion.
U bolesnika s refraktornim KLL-om, medijan smanjenja broja B stanica je bio 22% nakon prve infuzije i 92% nakon osme tjedne infuzije.